Shots:

• The company submitted applications to the US FDA & EMA seeking approval for Rinvoq (upadacitinib) for adults (15mg/30mg- qd) and adolescents (15mg- qd) with moderate to severe AD. The submission is based on three pivotal P-III studies and was studied without TCS in Measure Up 1 and Measure Up 2 and with TCS in AD Up
• Results: Rinvoq demonstrated an improvement in skin clearance and reduction in itch in adults and adolescents- met its co-1EPs including at least a 75% improvement in EASI 75 and a validated (vIGA-AD) score of 0/1 @16wks.- no new safety profile in observed
• Rinvoq is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. The submissions reinforce AbbVie's commitment to bringing Rinvoq to more patients living with immune-mediated diseases

 ­ Ref: Abbvie | Image: abbvie